Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great bounce off the low of the day! Shaping up to be a strong week!
Nice to see the support coming back!
I added another 800,000 between .031 & .034. I still can't believe we are trading at these levels!
Huge BID support, as weak hands and MM's games appear to be done.
I started buying VDRM at .006
I'm going to be one happy guy this month when we hit .10-.12+!!
I agree! I wouldn't be surprised if we made a run to .04 today.
News could hit any day!
A boat load of BUYS pouring in! Looking good here LONGS
Level2 looks really strong as well!
$VDRM
Good luck. 1,000,000 BID sitting at .03
We will run north soon!
$VDRM
So is .25, gltu
$VDRM
yaboy520, click on the link. Not hard to see what the float is!
Authorized Shares 400,000,000 a/o Mar 01, 2017
Outstanding Shares 309,232,603 a/o Mar 01, 2017
-Restricted 57,975,478 a/o Mar 01, 2017
-Unrestricted 251,257,125 a/o Mar 01, 2017
Held at DTC 246,331,609 a/o Mar 01, 2017
Float 222,337,825 a/o Jan 25, 2017
http://www.otcmarkets.com/stock/VDRM/profile
$VDRM
No kidding! People are nuts if they don't buy here!! IMHO
When news hits, hopefully sometime this week, they will be chasing above .05, and we will run to .10-12+
MM's can't push this much lower. Weeks hands are flushed out.
When people start ASK slapping we will start heading north again.
Chart is poised for a run.
I picked up another 800,000 today. Couldn't resist at these levels!
We will hit .10-.12+ this month
Revenues 2017
500,000 units x $125 = $62,500,000 starting Q2 2017
LOS ANGELES, CA--(Marketwired - February 03, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that they are placing the first order from their product manufacturer for a rollout of its FDA registered drug, Viabecline topical antibiotic. The Company expects sales for 2017 to be about 500,000 units and has completed financing to produce the orders. The rollout in California is expected to start with approximately 10,000 units being distributed online through an online network of affiliates. The products are anticipated to sell for approximately $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers.
"I believe these orders will give us a significant increase in revenues for 2017. ViaDerma has had clinical success in a very short time frame," said CEO Dr. Christopher Otiko. "We are excited to see our research being so well received in so many countries. This opens the door for many new products using FDA approved drugs along with our 'proprietary transdermal delivery system.’"
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Authorized Shares 400,000,000 a/o Mar 01, 2017
Outstanding Shares 309,232,603 a/o Mar 01, 2017
-Restricted 57,975,478 a/o Mar 01, 2017
-Unrestricted 251,257,125 a/o Mar 01, 2017
Held at DTC 246,331,609 a/o Mar 01, 2017
Float 222,337,825 a/o Jan 25, 2017
http://www.otcmarkets.com/stock/VDRM/profile
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Successful trial 96% success rate for diabetic foot ulcers...
$VDRM
Do people realize what kind of screaming BUYthis is?? LONGS do!!
Anyone who sold here will be chasing later. Mark this post!!
$VDRM
We've been trading between .035-.042 for the past week. Base has formed and we go up from here!
Once we hit .05 this week, next leg will be .10-.12
Easy triple from here! We will be trading at a new base of .10+ this month.
$VDRM
Great to see OWCP pop back up!
Retrace has started! 800,000 & 1,000,000 BIDs keeps popping up
Buy now people!
$VDRM
Don't fall for the MM games!
A 5mill Market Cap is insane!
We will be trading with a 100mill+ Market Cap once sales start rolling out!!!
Hit the ASK and we run!
$VDRM
stockzoom, I agree! We will pop soon.
Great buy at these prices!
1,200,000 at .035 on the BID
low volume MM games
Load up, MM want shares
$VDRM
No, 3,000,000 on Level2 aprox 20 minutes before close. There was a 2,000,000 BID along with another 1,000,000+ in smaller BIDs
trop, I agree. 3,000,000 was sitting on the BID at .04 just before close on Friday.
I think we're heading north tomorrow..
Your posts are false. Prove it
Smart money is already here. More to come this month.
.10 this month
.50 by summer
$$'s by year end!
$VDRM will be one of the biggest runners in 2017!
IndianaUSA. It's old news, and it's his ex that was arrested.
Everyone here artsy knows this!
harby58, I agree.
Currently trading at .041, with a Market Cap of 11.8mill.
Sales alone will put our Market Cap at .25+
Wait until the other patents are filed, with the trickle effect of those, and potential new licensing agreements etc., we will run into the $$'s IMO
GLTY
$VDRM
Great DD guys! I agree, this will be ViaDerma's year!
I've been here since .006 in January, and I've done a lot of DD with this company.
I stick to my targets..
.10 in March
.50 by summer
$$'s by year end. IMHO
Longs know what we have here, and we are not selling our shares.
Patience will pay off BIG
GLTA longs
$VDRM
WOW!! Over 3,000,000 sitting on the BID level2
$VDRM
JLUT, you are correct! Huge potential
Lots of level2 BID support, could very well have a green close going into Monday
Enjoy your weekend everyone!
Great things ahead for ViaDerma !!
$VDRM
Thanks DrDave. Appreciate the input.
I am planning on attending
$VDRM
JLUT, you've been around here long enough to know that the company refiled the patent in January 2017.
ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling Viabecline Through Established Online Distribution Networks in 2017
Marketwired MarketwiredJanuary 11, 2017
LOS ANGELES, CA--(Marketwired - January 11, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today that on December 14th, 2016, CEO Dr. Christopher Otiko filed a patent application with the USPTO for its proprietary innovative transdermal delivery system. ViaDerma has also signed licensing and distribution agreements with two Pharmaceuticals companies for its FDA registered drug, Viabecline. The OTC topical antibiotic is capable of significant healing results in just 10 days of treatment by combing a common FDA approved antibiotic, Tetracycline, with ViaDerma's proprietary transdermal delivery system. ViaDerma is seeing amazing penetration and absorption at the localized wound area. "We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido," said CEO Dr. Christopher Otiko.
"ViaDerma is ready to move forward in 2017. We are taking an aggressive growth path this year with product licensing deals that we expect to increase our revenue growth. We have many opportunities with the use of our proprietary transdermal delivery system for specialized treatments and continuing studies. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.
Viabecline, is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.
$VDRM
ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries
Marketwired MarketwiredFebruary 15, 2017Comment
LOS ANGELES, CA--(Marketwired - February 15, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today the "New Intellectual Property" & "New Products Initiative" will focus on creating new products and filing new patents to treat pain and certain diseases associated with inflammation. The company expects treatment success of ViaDerma's "Proprietary Delivery System" for several diseases by finding the "Optimal Transdermal Delivery" of CBD's & THC to the localized treatment area and into the blood stream. With regards to the patent pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The provisional patent application using the combination of CBD's with the delivery system was originally filed in 2014, and a new provisional patent will be filed this week. The patent pending transdermal system can deliver medications and nutrients into the body through the skin.
The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. "For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the carotid artery," said Dr. Christopher Otiko, CEO. "We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido."
ViaDerma sees the use of CBD's along with our Proprietary transdermal delivery system for the treatment and continuing studies looks very promising and demonstrates efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.
Thanks txhighopes!
What a strange day of trading!!
It will come, people will be chasing soon! MARK THIS POST!!
ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017, also Onychomycosis Clinical Studies Show Significant Results
Marketwired MarketwiredFebruary 3, 2017
LOS ANGELES, CA--(Marketwired - February 03, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that they are placing the first order from their product manufacturer for a rollout of its FDA registered drug, Viabecline topical antibiotic. The Company expects sales for 2017 to be about 500,000 units and has completed financing to produce the orders. The rollout in California is expected to start with approximately 10,000 units being distributed online through an online network of affiliates. The products are anticipated to sell for approximately $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers.
"I believe these orders will give us a significant increase in revenues for 2017. ViaDerma has had clinical success in a very short time frame," said CEO Dr. Christopher Otiko. "We are excited to see our research being so well received in so many countries. This opens the door for many new products using FDA approved drugs along with our 'proprietary transdermal delivery system.'"
"ViaDerma has also completed an initial clinical study of our proprietary medication for onychomycosis (toenail fungus), and the results were very encouraging with an approximate 80% success rate," said Dr. Otiko.
Onychomycosis affects approximately 5% of the worldwide population. One of the more popular medications on the market has a 17% success rate and can cost as much as $500 per 4ml bottle. Americans currently spend about $1.26 billion annually on oral and topical prescriptions for nail fungus, according to IMS Health, a health care information company. Industry analysts and executives estimate that more effective treatments could expand the market to as much as $3 billion annually.
"We are also in the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
Viabecline is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening. Significant results have been achieved in just 10 days of treatment using ViaDerma's proprietary transdermal delivery system.
$VDRM
I still haven't added a position here. I won't until they go live.
I haven't seen any news release, that's why I was asking.
Just checking in.. Did the company launch today?
Email him and ask him. He will be there.
$VDRM
casinoo, that's massive for the US if that bill gets passed! WOW
As for ViaDerma, ACCUMULATE all you can here!
.10+ is around the corner.
$VDRM
Some very smart people got some really cheap shares today!
Great to see the rebound!
$OWCP
In a few months, it won't matter. We will be trading .50+
$VDRM
Maybe1day, 3 days of posts..hmmm
People, VDRM has incredible UPSIDE!
Accumulate all you can under .05!!!
We will be trading $$'s the year. This is imho, but backed by the DD my group and I have done.
It'll come
$VDRM
One would hope! We will get there whether that's today or Monday.
I've concluded Neptune and IndianaUSA are not shareholders here. imo Odd that one only posts on the VDRM board..
This month we take off! We will hit .10+
$VDRM
DrDave, I disagree. Topical bypasses the liver and lungs, having the cbd transferred through the skin via ViaDermas technology is beyond HUGE. Every company will want this. Oil from the canibis plant, and having a way to have the body absorb the cbd bypassing the lungs and liver could be the golden ticket here.
I really believe we could be a 500mill+ company within the next few months.
Epic is coming!
$VDRM
I'll explain later, heading out for the afternoon.
$VDRM